ZBIO

Zenas BioPharma, Inc. (ZBIO) ESG Analysis Analysis (2026)

Invetso Score: 5.4/10 — Balanced · Last Updated: 2026-08-01

Environmental

R&D intensity is extremely high versus peers, which can support lower-waste innovation, but the metric also signals a materially resource-intensive operating model.

Negative gross margin suggests the company’s current process economics are less efficient than peers, which can indirectly increase environmental intensity per unit of output.

No direct emissions, energy, or waste disclosures were provided, limiting evidence that ZBIO outperforms peers on core environmental management.

The available metrics indicate a development-stage profile where environmental advantages are plausible, but peer-relative proof remains insufficient for a stronger score.

Social

Very high stock-based compensation relative to revenue can align employees with long-term value creation, but it also suggests heavy dilution pressure versus peers.

Elevated R&D spending supports scientific talent retention and innovation capacity, which is a positive social signal relative to less research-intensive peers.

No workforce safety, turnover, diversity, or product-responsibility disclosures were provided, so peer-relative social performance cannot be confirmed.

The company’s social profile appears mixed because talent investment is strong, yet the available data do not show a clear advantage over peers.

Governance

Stock-based compensation at 32.73% of revenue is high versus peers, indicating weaker capital discipline and potentially less shareholder-aligned governance.

Debt-to-equity of 1.58 is manageable, but the negative net debt-to-EBITDA metric reflects limited earnings visibility, which can weaken oversight quality versus peers.

Extremely high R&D intensity may be appropriate for a biotech model, yet it also raises execution-risk governance demands relative to more mature peers.

No board, audit, ownership, or controversy data were provided, so the score is driven mainly by compensation intensity and capital discipline concerns.

Overall Score

ZBIO’s ESG positioning is mixed and remains broadly in line with or slightly below peers because strong innovation intensity is offset by weak capital-discipline signals and limited disclosure.

Score Driver: High Stock-Based Compensation Relative To Revenue Is The Clearest Peer-Relative Governance Weakness.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Zenas BioPharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →